Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +85

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Drug approval Earnings report Licensing agreement AI-generated analysis

πŸ“ˆ Total revenues increased 36% year-over-year to $5.1 billion in Q3 2026, driven by strong performance across the core product portfolio.

πŸ’° GAAP EPS rose 35% to $18.45 and non-GAAP EPS surged 70% to $20.07, reflecting improved profitability and operational efficiency.

🀝 Sanofi collaboration expanded with a $1.0 billion up-front payment recognized in Q4 2026 and potential for up to $7.0 billion in future milestones.

βœ… FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva (FOP), validating the company's rare disease pipeline.

🌍 Libtayo received approval in Japan for cutaneous squamous cell carcinoma and a positive EMA opinion on an alternative dosing schedule.

πŸ’Š EYLEA HD U.S. net sales jumped 62% to $699 million, while Dupixent global sales grew 35% to $6.5 billion.

πŸ”¬ Pipeline advancements include encouraging early data in MASH, POTS, and ovarian cancer, with multiple Phase 3 programs advancing.

πŸ“‰ EYLEA U.S. net sales declined 41% due to competitive pressures and patient transition to the newer EYLEA HD formulation.

🏦 The company repurchased $2.3 billion of common stock during the nine months ended September 30, 2026.

πŸ’Έ A cash dividend of $0.94 per share was declared, payable on December 3, 2026.

Bullish Signals
  • Total revenues increased 36% to $5.1 billion in Q3 2026, marking the third consecutive quarter of double-digit growth.
  • Non-GAAP EPS surged 70% to $20.07, driven by strong commercial execution and a step-up in Sanofi collaboration revenue.
  • Dupixent global net sales reached a record $6.5 billion, increasing 35% year-over-year.
  • EYLEA HD U.S. net sales grew 62% to $699 million due to higher sales volumes and increased demand.
  • Libtayo global net sales increased 51% to $550 million, with U.S. sales rising 81%.
  • Expanded Sanofi collaboration added multiple next-generation antibodies with a $1.0 billion up-front payment recognized in Q4 2026.
  • FDA approved Pasatru for fibrodysplasia ossificans progressiva (FOP) following positive Phase 3 trial data showing sustained efficacy.
  • MHLW in Japan approved Libtayo as an adjuvant treatment for cutaneous squamous cell carcinoma, expanding its global footprint.
  • EMA adopted a positive opinion recommending an alternative dosing schedule for Libtayo to reduce frequency from every three weeks to every six weeks.
  • The company repurchased $2.3 billion of common stock in the first nine months of 2026, signaling confidence in its valuation.
Risk Factors
  • EYLEA U.S. net sales decreased 41% to $400 million due to lower sales volumes from competitive pressures and patient transition to EYLEA HD.
Full Analysis
Regeneron Pharmaceuticals reported robust third-quarter 2026 financial results, with total revenues surging 36% year-over-year to $5.1 billion. This growth was driven by record net sales across its core portfolio, including a 35% increase in Dupixent global sales (recorded by Sanofi), a 62% jump in EYLEA HD U.S. sales, and a 51% rise in Libtayo global sales. GAAP earnings per share increased 35% to $18.45, while non-GAAP EPS climbed 70% to $20.07, marking the third consecutive quarter of double-digit growth for both revenue and adjusted earnings. The company significantly expanded its strategic collaboration with Sanofi, adding multiple next-generation immunology antibodies to the alliance. This expansion included a substantial $1.0 billion up-front payment recognized as collaboration revenue in Q4 2026, with potential future milestones reaching up to an additional $7.0 billion. The agreement also stipulates that development and commercialization costs for these new programs will be shared equally between the partners. Beyond financial highlights, Regeneron achieved major regulatory milestones, including FDA approval for Pasatru (garetosmab) for fibrodysplasia ossificans progressiva (FOP) and MHLW approval in Japan for Libtayo as an adjuvant treatment for cutaneous squamous cell carcinoma. The company also received a positive opinion from the European Medicines Agency regarding an alternative dosing schedule for Libtayo, which could reduce dosing frequency to every six weeks after initial treatment.